Costa Carlos 4

What Happened

• Carlos Costa, Chief People Officer of Foghorn Therapeutics (FHTX), was granted a derivative equity award on January 30, 2026 representing 230,000 underlying shares with a strike/exercise price of $5.71 per share (total reported derivative value $1,313,300). This was an award/grant (not a purchase or sale), meaning no shares were sold or converted into cash at the time of the filing.

Key Details

• Transaction date: 2026-01-30; filing date: 2026-02-02 (appears timely).
• Grant: 230,000 underlying shares; exercise/strike price: $5.71; reported derivative value: $1,313,300.
• Transaction code: A (award/grant of derivative).
• Shares owned after the transaction: not disclosed in the Form 4 filing.
• Vesting (per footnote): 25% vests on Jan 30, 2027, then 6.25% of the underlying shares vest on the first day of each calendar quarter thereafter (standard ~4-year schedule).

Context

• This was an equity award (derivative) rather than an immediate purchase or sale; it gives the insider the right to acquire shares in the future subject to vesting and exercise. Such grants are common for executive compensation and do not by themselves indicate intent to buy or sell stock.